Floatz logo

Hryz-T101 Tcr-T Cell

Head and Neck Squamous Cell Carcinoma

HRYZ Biotech Co.Cell therapyPhase 1Active
C
37/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
28/ 100
Competitive Position
65/ 100

Competitive context

249 Active assets in the Head and Neck Squamous Cell Carcinoma cohort.

Asset / SponsorPhaseRating
Carboplatin
Akeso
Phase 4BB
CIS-DIAMMINEDICHLOROPLATINUM II
Akeso
Phase 3BB
Irinotecan
Neonc Technologies, Inc.
Phase 2BB
Tisotumab Vedotin
Seagen, a wholly owned subsidiary of Pfizer
Phase 2BB
Capecitabine
Merck Sharp & Dohme LLC
Phase 2BB

View all 50 →

Same molecule, other indications

Hryz-T101 Tcr-T Cell is also rated in:

oropharyngeal carcinomaDormant
CC
Indicative ·
43 / 100
View asset →
vaginal neoplasmDormant
CC
Indicative ·
43 / 100
View asset →
penile carcinomaDormant
CC
Indicative ·
43 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →